top of page
Browse by category
Search


Omada survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals
Omada Health has released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers...

Journal Watch 30/10/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Skeletal muscle health concerns with the rise of weight loss medications
A commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically...


GLP-1 use doubles as bariatric surgery declines by 25%
A study by researchers at Brigham and Women's Hospital, in collaboration with researchers at Harvard TH Chan School of Public Health and...


Costs of obesity management medications exceeds BMS in less than a year
The cost of taking weekly injections of popular obesity management medications liraglutide (Saxenda) or semaglutide (Wegovy) exceeds that...

Bariatric surgery outperforms GLP-1 diabetes drugs for kidney protection
For patients with type 2 diabetes, obesity and chronic kidney disease, bariatric surgery was associated with a significant decrease in...

Amycretin achieves 13% weight loss within three months with once-a-day tablet
Individuals who received a once-a-day oral weight loss drug, Amycretin developed by Novo Nordisk, lost up to 13% of their body weight...


Strong relationship between the increase in metabolic activity caused by once-daily GLP-1 and the amount of weight lost
A study carried out in St Vincent's University Hospital (SVUH) Dublin, Ireland, challenges the belief that weight-loss medications such...

GLP-1 RAs alone are not enough for individuals to achieve health goals
A group of obesity management professionals led by University College London have acknowledged the promise of the new generation of...


Popularity of GLP-1s among privately insured patients may worsen disparities
Publicly insured US individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than...
Browse by tag






bottom of page